V Lamounier-Zepter1, C Look1, W-H Schunck2, I Schlottmann1, C Woischwill1, S R Bornstein1, A Xu3, I Morano2. 1. Medical Clinic III, University of Technology Dresden, Dresden, Germany. 2. Max-Delbrück-Center for Molecular Medicine, Berlin-Buch, Germany. 3. State Key Laboratory of Pharmaceutical Biotechnology and Department of Medicine, University of Hong Kong, Hong Kong, China.
Abstract
BACKGROUND: Adipocyte fatty acid-binding protein (FABP4) is a member of a highly conserved family of cytosolic proteins that bind with high affinity to hydrophobic ligands, such as saturated and unsaturated long-chain fatty acids and eicosanoids. Recent evidence has supported a novel role for FABP4 in linking obesity with metabolic and cardiovascular disorders. In this context, we identified FABP4 as a main bioactive factor released from human adipose tissue that directly suppresses heart contraction in vitro. As FABP4 is known to be a transport protein, it cannot be excluded that lipid ligands are involved in the cardiodepressant effect as well, acting in an additional and/or synergistic way. OBJECTIVE: We investigated a possible involvement of lipid ligands in the negative inotropic effect of adipocyte factors in vitro. RESULTS: We verified that blocking the CYP epoxygenase pathway in adipocytes attenuates the inhibitory effect of adipocyte-conditioned medium (AM) on isolated adult rat cardiomyocytes, thus suggesting the participation of epoxyeicosatrienoic acids (EETs) in the cardiodepressant activity. Analysis of AM for EETs revealed the presence of 5,6-, 8,9-, 11,12- and 14,15-EET, whereas 5,6-EET represented about 45% of the total EET concentration in AM. Incubation of isolated cardiomyocytes with EETs in similar concentrations as found in AM showed that 5,6-EET directly suppresses cardiomyocyte contractility. Furthermore, after addition of 5,6-EET to FABP4, the negative inotropic effect of FABP4 was strongly potentiated in a concentration-dependent manner. CONCLUSIONS: These data suggest that adipocytes release 5,6-EET and FABP4 into the extracellular medium and that the interaction of these factors modulates cardiac function. Therefore elevated levels of FABP4 and 5,6-EET in obese patients may contribute to the development of heart dysfunction in these subjects.
BACKGROUND: Adipocyte fatty acid-binding protein (FABP4) is a member of a highly conserved family of cytosolic proteins that bind with high affinity to hydrophobic ligands, such as saturated and unsaturated long-chain fatty acids and eicosanoids. Recent evidence has supported a novel role for FABP4 in linking obesity with metabolic and cardiovascular disorders. In this context, we identified FABP4 as a main bioactive factor released from human adipose tissue that directly suppresses heart contraction in vitro. As FABP4 is known to be a transport protein, it cannot be excluded that lipid ligands are involved in the cardiodepressant effect as well, acting in an additional and/or synergistic way. OBJECTIVE: We investigated a possible involvement of lipid ligands in the negative inotropic effect of adipocyte factors in vitro. RESULTS: We verified that blocking the CYP epoxygenase pathway in adipocytes attenuates the inhibitory effect of adipocyte-conditioned medium (AM) on isolated adult rat cardiomyocytes, thus suggesting the participation of epoxyeicosatrienoic acids (EETs) in the cardiodepressant activity. Analysis of AM for EETs revealed the presence of 5,6-, 8,9-, 11,12- and 14,15-EET, whereas 5,6-EET represented about 45% of the total EET concentration in AM. Incubation of isolated cardiomyocytes with EETs in similar concentrations as found in AM showed that 5,6-EET directly suppresses cardiomyocyte contractility. Furthermore, after addition of 5,6-EET to FABP4, the negative inotropic effect of FABP4 was strongly potentiated in a concentration-dependent manner. CONCLUSIONS: These data suggest that adipocytes release 5,6-EET and FABP4 into the extracellular medium and that the interaction of these factors modulates cardiac function. Therefore elevated levels of FABP4 and 5,6-EET in obesepatients may contribute to the development of heart dysfunction in these subjects.
Authors: Meetha Medhora; John Daniels; Kavita Mundey; Beate Fisslthaler; Rudi Busse; Elizabeth R Jacobs; David R Harder Journal: Am J Physiol Heart Circ Physiol Date: 2002-09-26 Impact factor: 4.733
Authors: C A Baxa; R S Sha; M K Buelt; A J Smith; V Matarese; L L Chinander; K L Boundy; D A Bernlohr Journal: Biochemistry Date: 1989-10-31 Impact factor: 3.162
Authors: Lu Liu; Nitin Puri; Marco Raffaele; Joseph Schragenheim; Shailendra P Singh; J Alyce Bradbury; Lars Bellner; Luca Vanella; Darryl C Zeldin; Jian Cao; Nader G Abraham Journal: Prostaglandins Other Lipid Mediat Date: 2018-07-21 Impact factor: 3.072
Authors: Dominika Klimczak-Tomaniak; Marie de Bakker; Elke Bouwens; K Martijn Akkerhuis; Sara Baart; Dimitris Rizopoulos; Henk Mouthaan; Jan van Ramshorst; Tjeerd Germans; Alina Constantinescu; Olivier Manintveld; Victor Umans; Eric Boersma; Isabella Kardys Journal: Sci Rep Date: 2022-02-18 Impact factor: 4.379
Authors: E Sommariva; S Brambilla; C Carbucicchio; E Gambini; V Meraviglia; A Dello Russo; F M Farina; M Casella; V Catto; G Pontone; M Chiesa; I Stadiotti; E Cogliati; A Paolin; N Ouali Alami; C Preziuso; G d'Amati; G I Colombo; A Rossini; M C Capogrossi; C Tondo; G Pompilio Journal: Eur Heart J Date: 2015-11-20 Impact factor: 29.983
Authors: Danielle F Vileigas; Victoria M Harman; Paula P Freire; Cecília L C Marciano; Paula G Sant'Ana; Sérgio L B de Souza; Gustavo A F Mota; Vitor L da Silva; Dijon H S Campos; Carlos R Padovani; Katashi Okoshi; Robert J Beynon; Lucilene D Santos; Antonio C Cicogna Journal: Sci Rep Date: 2019-12-02 Impact factor: 4.379